State Street Corp Boosts Stock Holdings in Qiagen (NYSE:QGEN)

State Street Corp increased its holdings in Qiagen (NYSE:QGEN - Free Report) by 3.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,380,008 shares of the company's stock after buying an additional 90,181 shares during the period. State Street Corp owned 1.04% of Qiagen worth $108,457,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Quantinno Capital Management LP raised its holdings in shares of Qiagen by 31.2% during the third quarter. Quantinno Capital Management LP now owns 78,707 shares of the company's stock valued at $3,562,000 after acquiring an additional 18,716 shares in the last quarter. Point72 DIFC Ltd lifted its holdings in shares of Qiagen by 10,610.4% during the third quarter. Point72 DIFC Ltd now owns 649,693 shares of the company's stock valued at $29,606,000 after purchasing an additional 643,627 shares in the last quarter. Holocene Advisors LP purchased a new position in Qiagen in the 3rd quarter worth about $9,991,000. Point72 Hong Kong Ltd grew its position in Qiagen by 172.2% in the 3rd quarter. Point72 Hong Kong Ltd now owns 64,161 shares of the company's stock worth $2,924,000 after purchasing an additional 40,589 shares during the period. Finally, PDT Partners LLC boosted its position in Qiagen by 77.1% in the third quarter. PDT Partners LLC now owns 104,424 shares of the company's stock worth $4,759,000 after purchasing an additional 45,449 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Shares of NYSE QGEN traded down $0.02 during trading on Monday, hitting $45.38. The company had a trading volume of 806,469 shares, compared to its average volume of 1,140,199. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a fifty day simple moving average of $43.25 and a two-hundred day simple moving average of $43.74. The firm has a market capitalization of $10.36 billion, a price-to-earnings ratio of 116.36, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of analyst reports. Jefferies Financial Group reaffirmed a "buy" rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a "hold" rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $51.15.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.